Literature DB >> 24865967

PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.

Jeroen Paardekooper Overman1, Jae-Sung Yi2, Monica Bonetti1, Matthew Soulsby2, Christian Preisinger3, Matthew P Stokes4, Li Hui4, Jeffrey C Silva4, John Overvoorde1, Piero Giansanti3, Albert J R Heck3, Maria I Kontaridis5, Jeroen den Hertog6, Anton M Bennett7.   

Abstract

Noonan syndrome (NS) is an autosomal dominant disorder caused by activating mutations in the PTPN11 gene encoding Shp2, which manifests in congenital heart disease, short stature, and facial dysmorphia. The complexity of Shp2 signaling is exemplified by the observation that LEOPARD syndrome (LS) patients possess inactivating PTPN11 mutations yet exhibit similar symptoms to NS. Here, we identify "protein zero-related" (PZR), a transmembrane glycoprotein that interfaces with the extracellular matrix to promote cell migration, as a major hyper-tyrosyl-phosphorylated protein in mouse and zebrafish models of NS and LS. PZR hyper-tyrosyl phosphorylation is facilitated in a phosphatase-independent manner by enhanced Src recruitment to NS and LS Shp2. In zebrafish, PZR overexpression recapitulated NS and LS phenotypes. PZR was required for zebrafish gastrulation in a manner dependent upon PZR tyrosyl phosphorylation. Hence, we identify PZR as an NS and LS target. Enhanced PZR-mediated membrane recruitment of Shp2 serves as a common mechanism to direct overlapping pathophysiological characteristics of these PTPN11 mutations.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24865967      PMCID: PMC4135572          DOI: 10.1128/MCB.00135-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  Morphogenetic movements at gastrulation require the SH2 tyrosine phosphatase Shp2.

Authors:  T M Saxton; T Pawson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.

Authors:  John Rush; Albrecht Moritz; Kimberly A Lee; Ailan Guo; Valerie L Goss; Erik J Spek; Hui Zhang; Xiang-Ming Zha; Roberto D Polakiewicz; Michael J Comb
Journal:  Nat Biotechnol       Date:  2004-12-12       Impact factor: 54.908

3.  Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.

Authors:  Nadine Hanna; Alexandra Montagner; Wen Hwa Lee; Maria Miteva; Michel Vidal; Michel Vidaud; Béatrice Parfait; Patrick Raynal
Journal:  FEBS Lett       Date:  2006-04-12       Impact factor: 4.124

4.  PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.

Authors:  Maria I Kontaridis; Kenneth D Swanson; Frank S David; David Barford; Benjamin G Neel
Journal:  J Biol Chem       Date:  2005-12-23       Impact factor: 5.157

5.  Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.

Authors:  M Golam Mohi; Ifor R Williams; Charles R Dearolf; Gordon Chan; Jeffery L Kutok; Sarah Cohen; Kelly Morgan; Christina Boulton; Hirokazu Shigematsu; Heike Keilhack; Koichi Akashi; D Gary Gilliland; Benjamin G Neel
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

6.  Fyn/Yes and non-canonical Wnt signalling converge on RhoA in vertebrate gastrulation cell movements.

Authors:  Chris Jopling; Jeroen den Hertog
Journal:  EMBO Rep       Date:  2005-05       Impact factor: 8.807

7.  Purification and cloning of PZR, a binding protein and putative physiological substrate of tyrosine phosphatase SHP-2.

Authors:  Z J Zhao; R Zhao
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

Review 8.  Noonan syndrome and related disorders: genetics and pathogenesis.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Annu Rev Genomics Hum Genet       Date:  2005       Impact factor: 8.929

9.  An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival.

Authors:  Wentian Yang; Lori D Klaman; Binbin Chen; Toshiyuki Araki; Hisashi Harada; Sheila M Thomas; Elizabeth L George; Benjamin G Neel
Journal:  Dev Cell       Date:  2006-03       Impact factor: 12.270

10.  Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.

Authors:  Marco Tartaglia; Simone Martinelli; Lorenzo Stella; Gianfranco Bocchinfuso; Elisabetta Flex; Viviana Cordeddu; Giuseppe Zampino; Ineke van der Burgt; Antonio Palleschi; Tamara C Petrucci; Mariella Sorcini; Claudia Schoch; Robin Foa; Peter D Emanuel; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2005-12-07       Impact factor: 11.025

View more
  16 in total

Review 1.  Mining the function of protein tyrosine phosphatases in health and disease.

Authors:  Hojin Lee; Jae-Sung Yi; Ahmed Lawan; Kisuk Min; Anton M Bennett
Journal:  Semin Cell Dev Biol       Date:  2014-09-26       Impact factor: 7.727

2.  SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis.

Authors:  Argyrios Tzouvelekis; Guoying Yu; Christian L Lino Cardenas; Jose D Herazo-Maya; Rong Wang; Tony Woolard; Yi Zhang; Koji Sakamoto; Hojin Lee; Jae-Sung Yi; Giuseppe DeIuliis; Nikolaos Xylourgidis; Farida Ahangari; Patty J Lee; Vassilis Aidinis; Erica L Herzog; Robert Homer; Anton M Bennett; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

Review 3.  The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease.

Authors:  Jessica Lauriol; Fabrice Jaffré; Maria I Kontaridis
Journal:  Semin Cell Dev Biol       Date:  2014-09-22       Impact factor: 7.727

Review 4.  LITTLE FISH, BIG DATA: ZEBRAFISH AS A MODEL FOR CARDIOVASCULAR AND METABOLIC DISEASE.

Authors:  Philipp Gut; Sven Reischauer; Didier Y R Stainier; Rima Arnaout
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

Review 5.  An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies.

Authors:  Jae-Sung Yi; Sravan Perla; Anton M Bennett
Journal:  Cardiovasc Drugs Ther       Date:  2022-02-14       Impact factor: 3.727

6.  Dissecting protein tyrosine phosphatase signaling by engineered chemogenetic control of its activity.

Authors:  Jordan Fauser; Vincent Huyot; Jacob Matsche; Barbara N Szynal; Yuri Alexeev; Pradeep Kota; Andrei V Karginov
Journal:  J Cell Biol       Date:  2022-07-13       Impact factor: 8.077

Review 7.  Friend or foe? Unraveling the complex roles of protein tyrosine phosphatases in cardiac disease and development.

Authors:  Maike Krenz
Journal:  Cell Signal       Date:  2022-03-05       Impact factor: 4.850

8.  Low-dose dasatinib rescues cardiac function in Noonan syndrome.

Authors:  Jae-Sung Yi; Yan Huang; Andrea T Kwaczala; Ivana Y Kuo; Barbara E Ehrlich; Stuart G Campbell; Frank J Giordano; Anton M Bennett
Journal:  JCI Insight       Date:  2016-12-08

9.  Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.

Authors:  Jae-Sung Yi; Sravan Perla; Yan Huang; Kana Mizuno; Frank J Giordano; Alexander A Vinks; Anton M Bennett
Journal:  Cardiovasc Drugs Ther       Date:  2021-03-10       Impact factor: 3.947

10.  Integrated in silico MS-based phosphoproteomics and network enrichment analysis of RASopathy proteins.

Authors:  Javier-Fernando Montero-Bullón; Óscar González-Velasco; María Isidoro-García; Jesus Lacal
Journal:  Orphanet J Rare Dis       Date:  2021-07-06       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.